article thumbnail

France's Orano Med debuts radiotherapy manufacturing plant near Indianapolis

Fierce Pharma

to establish a manufacturing plant as it progresses on its radiopharma journey. The site marks the world’s first industrial-scale facility dedicated to production of lead-212-based radioligand therapies, the company said. Amid a nuclear medicine boom, France’s Orano Med has chosen the U.S.

article thumbnail

Aurisco Pharmaceutical Launches State-of-the-Art Manufacturing Facility for GLP-1 Peptides

Fierce Pharma

[Yangzhou, China - March 26, 2024] - Aurisco Pharmaceutical, a leading global pharmaceutical company, is excited to announce the completion of its investment in cGMP peptide manufacturing capacity | Aurisco Pharmaceutical Launches State-of-the-Art Manufacturing Facility for GLP-1 Peptides

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Modifier gene therapy – clinical development and manufacturing considerations

European Pharmaceutical Review

Tell us about Ocugen’s lead programme, OCU400. Unlike conventional methods…modifier gene therapy…emphasises the importance of the broader biological system, potentially leading to more effective treatments.” What are the top three challenges associated with gene therapy manufacturing?

article thumbnail

Harmonizing next-gen MES with traditional approaches for smarter manufacturing

Fierce Pharma

Olivia Gannon, Associate Director of Global MES and Digital Execution Systems, Life Sciences Manufacturing, Cognizant, explores how a digitalization strategy harnessing the latest innovatio | Olivia Gannon, Global MES Service Line Lead at Cognizant, explores how a digitalization strategy harnessing the latest innovations in MES technologies can help (..)

article thumbnail

Bayer christens $250M cell therapy 'launch facility' in Berkeley

Fierce Pharma

Despite the promise of cell therapies, manufacturing the personalized medicines at scale has been a limiting factor for many companies. Despite the promise of cell therapies, manufacturing the personalized medicines at scale has been a limiting factor for many companies.

article thumbnail

Innovative radioligand manufacturing facility inaugurated

European Pharmaceutical Review

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. This news follows the company beginning construction on a similar facility in France , which is set to produce lead-212 radioligand therapies for the European market.

article thumbnail

‘Accidental’ media switch leads to CAR T therapy discovery

European Pharmaceutical Review

Putting T cells on a keto diet [putting our T cells on a three-day ‘keto’ diet] showed reduced maturity at the end of the manufacturing process. “We discovered that by briefly restricting sugar exposure, akin to a three-day ‘keto diet,’ our T cells showed reduced maturity at the end of the manufacturing process.

Media 116